Overview

A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.

Status:
Completed
Trial end date:
2016-05-26
Target enrollment:
Participant gender:
Summary
This study is a double-blind randomized, placebo-controlled, parallel-group, 12 week study performed in 2 centres in Sweden to assess the effect of Omega-3 carboxylic acids and fenofibrate on liver fat measured with magnetic resonance imaging (MRI) in patients with over-weight and hypertriglyceridemia.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Fenofibrate